Humira
| Year | US sales | vs 2022 |
|---|---|---|
| 2022 | $18.62B | 100% |
| 2023 | $12.16B | 65% |
| 2024 | $7.14B | 38% |
| 2025 | $3.06B | 16% |
US biosimilars launched through 2023. Outside the US, where biosimilars arrived in 2018, AbbVie still reported $1.5B of Humira sales in 2025.
What actually happened to US sales once generics or biosimilars arrived, from the companies' own filings. Each line starts at the last full year before copies launched (100%).
Hover or tap a point for the dollar figure; on a phone, scroll the chart sideways. Year 1 is the first calendar year with copies on the US market; for Tecfidera that year includes seven months before generics launched.
Humira: US sales were down to 65% in 2023, 38% in 2024 and 16% in 2025, measured against 2022.
Stelara: US sales were 57% in 2025, measured against 2024.
Tecfidera: US sales were down to 81% in 2020, 21% in 2021 and 13% in 2022, measured against 2019.
Revlimid: US sales were down to 96% in 2022, 61% in 2023, 57% in 2024 and 29% in 2025, measured against 2021.
How copies enter matters as much as what kind of drug it is. Tecfidera faced unrestricted generics and lost most of its US sales in its first full year of generics. Revlimid's settlements capped generic volumes for four years, so it declined gradually despite also being a small molecule. Both biologics here lost around 35% to 45% in their first year of biosimilars.
| Year | US sales | vs 2022 |
|---|---|---|
| 2022 | $18.62B | 100% |
| 2023 | $12.16B | 65% |
| 2024 | $7.14B | 38% |
| 2025 | $3.06B | 16% |
US biosimilars launched through 2023. Outside the US, where biosimilars arrived in 2018, AbbVie still reported $1.5B of Humira sales in 2025.
| Year | US sales | vs 2024 |
|---|---|---|
| 2024 | $6.72B | 100% |
| 2025 | $3.85B | 57% |
Several biosimilars launched within months of each other. J&J also cites the Medicare Part D redesign as a factor.
| Year | US sales | vs 2019 |
|---|---|---|
| 2019 | $3.30B | 100% |
| 2020 | $2.68B | 81% |
| 2021 | $0.68B | 21% |
| 2022 | $0.42B | 13% |
Unrestricted generic entry. 2020 includes seven months before generics; 2019 is US fumarate revenue less about $11M of Vumerity.
| Year | US sales | vs 2021 |
|---|---|---|
| 2021 | $8.70B | 100% |
| 2022 | $8.36B | 96% |
| 2023 | $5.27B | 61% |
| 2024 | $5.00B | 57% |
| 2025 | $2.54B | 29% |
Settlements capped generic volumes for four years, so the decline was gradual. 2024 onward is from later 10-Ks, which restate 2023 about 1% lower.